Disproportionality statistics for signal detection
|
|
- Nancy Fitzgerald
- 6 years ago
- Views:
Transcription
1 Disproportionality statistics for signal detection Andrew Bate Senior Director, Analytics Team Lead, Epidemiology ISOP-UMC Training Course Mysore, 13 January 2015
2 Disclosures I am a full time employee of Pfizer and hold stocks and stock options
3 Spontaneous reporting as a tool for post marketing surveillance Analysis of spontaneous reports of suspected adverse drug reactions (ADRs) is a valuable tool in the detection of previously unknown drug adverse reactions Reports of adverse events (AEs) associated with a drug are not necessarily true ADRs, that is, they may be temporally associated with a drug but not caused by the drug. Hypothesis generation of new possible side effects from such data is referred to as signal detection Ref Bate and Evans 2009 PDS
4 Signal of suspected causality - definition Information that arises from one or multiple sources (including observations and experiments), which suggests a new potentially causal association, or a new aspect of a known association, between an intervention and an event or set of related events, either adverse or beneficial, that is judged to be of sufficient likelihood to justify verificatory action. Ref CIOMS VIII Practical Aspects of Signal Detection in Pharmacovigilance 2009
5 Spontaneous reporting limitations Often limited clinical information on reports and satisfactory secondary case evaluation is not always possible Not all ADRs that occur will be recognized as drug induced by a healthcare professional Even those that are suspected will not necessarily be reported Suspicion can mistakenly rest on the drug, coincidental spontaneous ADR case reports resulting Control information is not collected as part of spontaneously reported systems, the drug use is not known, and there is no direct information on disease incidence Ref Bate et al 2008 FCP
6 Quantitative signal detection To detect potential signals for further investigation that are not readily recognisable on a single case report nor otherwise readily apparent at case entry Enhance rather than replace other methods of signal detection E.g. Initial case review of spontaneous reports Overall help to detect signals earlier, more effectively and more efficiently Primarily useful in large data sets
7 Quantitative signal detection different approaches Several methods for screening spontaneously reported data Most common approach: measures of disproportionality Different measures of disproportionality But all aim to detect the unexpectedly frequently reported relative to a background of other reports Quantitative outputs clinically reviewed and some subsequently considered as signals
8 Metrics used in quantitative screening of spontaneous reports 2 by 2 contingency table AE of interest (y) Other AEs Drug of interest (x) a b Other drugs c d Proportional Reporting Ratio (PRR) = [a (a + b)] / [c (c + d)] Reporting Odds Ratio (ROR) = [a b] / [c (d)] Observed / Expected 1 = 1 Frequentist basis of EBGM and IC 8 [a (a + b)] / [(a + c) (a + b + c + d)] See Bate and Evans 2009 PDS, for an overview
9 Bayesian methods in quantitative signal detection - Bayesian methods give framework for how to combine prior information with data - Prior information/knowledge + data - Account in a conceptually transparent way for external data and/or subjective opinion - Bayesian methods - not always more complex IC log 2 Observed Expected + + 1/ 2 1/ 2 Refs Noren et al 2013, for IC formula Bate and Evans 2009 PDS, for an overview - High Observed and Expected, shrinkage no practical impact - When Expected and Observed are low, IC tends to zero - Note: Idea is that overall the estimates will be better not that each estimate will necessarily be better Informative priors also possible
10 Change in Information Component over time Captopril - Coughing IC -2 79:1 81:1 83:1 85:1 87:1 89:1 91:1 93:1 95:1 Time(year)
11 Change in Information Component over time 6 Digoxin - Rash IC -6 67:1 70:1 73:1 76:1 79:1 82:1 85:1 88:1 91:1 94:1 Time(year)
12 Change in Information Component over time Digoxin - Acne IC -6 67:1 70:1 73:1 76:1 79:1 82:1 85:1 88:1 91:1 94:1 Time(year)
13 Change in Information Component over time Practolol, ATC C07AB - Peritonitis sclerosing Practolol ATC C07AB year
14 Differences in metrics The best metric No single best method PRR arguably most easy to interpret Shrinkage in Bayesian approaches advantageous at low counts, but more complex Van Puijenbroek et al 2001 Underreporting less effect for ROR than PRR Van Der Heijden 2002, Rothman et al 2004 ROR gives more volatile scores 14
15 Choice of metrics ROR =4.24, PRR= 3.59, O/E= 3.33
16 Choice of metrics ROR =3.88, PRR= 3.59, O/E= 3.33
17 Ongoing Misunderstanding The PRR of 6 indicates that for this drug the risk of reporting this event is six times higher compared with reference drugs. Should be: The PRR of 6 indicates that for this drug the probability of reporting this particular event rather than any other event is six times higher compared to the probability for reference drugs 17
18 Background reading Bate A et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 1998; 54: Bate A, Lindquist M, and Edwards IR. The application of knowledge discovery in databases to postmarketing drug safety: example of the WHO database. Fundam Clin Pharmacol, (2): p Bate A, Evans SJW Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiology and Drug Safety. 18(6): DuMouchel, W. (1999). Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. The American Statistician, 53(3), Evans, S. J. W., Waller, P. C., & Davis, S. (2001). Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiology and drug safety, 10(6), Gipson, G. (2012). A shrinkage based comparative assessment of observed to expected disproportionality measures. Pharmacoepidemiology and drug safety, 21(6), Lindquist M et al. From association to alert - A revised approach to international signal analysis. Pharmacoepidemiology and Drug Safety 1999; 8: S15-S25 Norén GN, Hopstadius J, Bate A Shrinkage observed to expected ratios for robust and transparent large scale pattern discovery. Statistical Methods in Medical Research. 22 (1), van Puijenbroek EM et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for Adverse Drug Reactions. Pharmacoepidemiology and Drug Safety 2002; Volume 11( 1) pp
19 Conclusions Several methods for screening spontaneously reported data Most common approach: measures of disproportionality Different measures of disproportionality But all aim to detect the unexpectedly frequently reported relative to a background of other reports No one best method Quantitative outputs clinically reviewed and some subsequently considered as signals Quantitative signal detection needs to be part of robust overall signal management programme
Disproportionality Analysis and Its Application to Spontaneously Reported Adverse Events in Pharmacovigilance
WHITE PAPER Disproportionality Analysis and Its Application to Spontaneously Reported Adverse Events in Pharmacovigilance Richard C. Zink, SAS, Cary, NC Table of Contents Introduction... 1 Spontaneously
More informationInt. J. Pharm. Sci. Rev. Res., 28(2), September October 2014; Article No. 18, Pages:
Research Article Signal Detection - An Imperative Activity of Pharmacovigilance Satish Chandel*, Nidhi Jain, Abhay Joshi, Rakesh Sonawane, Arvind Sharma, Satish Chandel Department of Pharmacology, Gandhi
More informationMircea Ciuca, MD Global Head Medical & Clinical Drug Safety
Mircea Ciuca, MD Global Head Medical & Clinical Drug Safety Disclaimer The views and opinions expressed in this presentation are solely those of the presenter and do not necessarily reflect those of Vifor,
More informationPharmacovigilance and methods of Signal Detection
Indian Journal of Pharmacy Practice Association of Pharmaceutical Teachers of India Pharmacovigilance and methods of Signal Detection Trusha Patel M.Pharm (Clinical Pharmacy), K.B.Institute of pharmaceutical
More informationApplied Bayesian Approaches in Safety and Pharmacovigilance
Applied Bayesian Approaches in Safety and Pharmacovigilance Professor Andy Grieve Department of Public Health Sciences King s College, London Andy.Grieve@kcl.ac.uk 1 Outline Safety is an issue in all phases
More informationPharmacovigilance. Training session for patients and consumers involved in EMA activities, 25 November Presented by: Priya Bahri
Pharmacovigilance Training session for patients and consumers involved in EMA activities, 25 November 2014 Presented by: Priya Bahri An agency of the European Union 2 Pharmacovigilance - the science concerned
More informationImpact of Stratification on Adverse Drug Reaction Surveillance
Drug Safety 8; 31 (11): 135-148 ORIGINAL RESEARCH ARTICLE 114-5916/8/11-135/$48./ 8 Adis Data Information BV. All rights reserved. Impact of Stratification on Adverse Drug Reaction Surveillance Johan Hopstadius,
More informationData Mining of Report Databases: Adverse Drug Reactions vs. Automobile Safety Defects
Data Mining of Report Databases: Adverse Drug Reactions vs. Automobile Safety Defects William DuMouchel Oracle Health Sciences Committee for a Study of Electronic Vehicle Controls and Unintended Acceleration
More informationInternational Journal of Chemistry and Pharmaceutical Sciences. International Journal of Chemistry and Pharmaceutical Sciences
International Journal of Chemistry and Pharmaceutical Sciences Journal Home Page: www.pharmaresearchlibrary.com/ijcps Review Article Open Access Pharmacovigilance Methods: A Review Musali Muni kumari *,
More informationQuality check of spontaneous adverse drug reaction reporting forms of different countries y
pharmacoepidemiology and drug safety (2010) Published online in Wiley Online Library (wileyonlinelibrary.com).2004 ORIGINAL REPORT Quality check of spontaneous adverse drug reaction reporting forms of
More informationPHARMACOVIGILANCE IN AND EMERGING MARKETS: AN INDUSTRY PERSPECTIVE. Shashidhar Swamy (Head, Pharmacovigilance) Wockhardt limited, Mumbai
PHARMACOVIGILANCE IN AND EMERGING MARKETS: AN INDUSTRY PERSPECTIVE Shashidhar Swamy (Head, Pharmacovigilance) Wockhardt limited, Mumbai 1 Disclaimer The content expressed in this presentation is solely
More informationGuideline on good pharmacovigilance practices (GVP)
22 June 2012 EMA/827661/2011 (superseded version) Guideline on good pharmacovigilance practices (GVP) Module IX Signal management Draft finalised by the Agency in collaboration with Member States and submitted
More informationSCOPE Work Package 5 Survey Report
SCOPE Work Package 5 Survey Report Topic: Signal Management Authors: Alexandra Pacurariu Anja van Haren Anna-Lena Berggren Birgitta Grundmark Helle Harder Mona Vestergaard Laursen Paul Barrow Phil Tregunno
More informationAdvance Topics in Pharmacoepidemiology. Risk Management. Conflict of Interest Declaration. Benefit Harm Profile?
Advance Topics in Pharmacoepidemiology Risk Management 2012 Mid-Year ISPE Meeting Miami, April 21-23, 2012 Ariel E., Arias MD, PhD - Fac. Pharmacy; Université de Montréal - Biologics & Genetic Therapies
More informationPROTECT s Impact on Pharmacovigilance Practice: An Industry Perspective
PROTECT s Impact on Pharmacovigilance Practice: An Industry Perspective Robert Reynolds, ScD Vice President, Epidemiology Pfizer Research & Development ICPE Boston August 25, 2015 Disclosures I am an employee
More informationPharmacovigilance & Signal Detection
Pharmacovigilance & Signal Detection 30 th International Conference on Pharmacoepidemiology & Therapeutic Risk Management Pre-conference educational session Thursday, October 23, 2014; 2:00-6:00pm Semi-automated,
More informationCommentary POLICY. Key words: Adverse drug reaction; India; Pharmacovigilance; Uppsala monitoring center
Pharmacovigilance Programme of India Duvvuru Ashok Kumar 1 *, Languluri Reddenna 1, Shaik Ayub Basha 1 1 Department of Pharm-D, P. Rami Reddy Memorial College of Pharmacy, Kadapa, Andhra Pradesh, India-516003
More informationContact Information: Rapture Biotech D-201, Sector - 10, Noida Uttar Pradesh. Phone , ,
Topics Covered: MODULE 1 Introduction To Pharmacovigilance Terminologies used in Pharmacovigilance ADRs Polypharmacy MODULE 2 Pharmacoepidemiology Iatrogenesis Prescription-event monitoring MODULE 3 SAE
More informationGuideline on good pharmacovigilance practices (GVP)
9 October 2017 EMA/827661/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module IX Signal management (Rev 1) Date of coming into effect of first version 2 July 2012 Draft Revision 1* finalised
More informationIntegrating and Using Siebel Analytics for AERS 4.6 Signal Detection
Integrating and Using Siebel Analytics for AERS 4.6 Signal Detection Presented by Sunil G. Singh Jian Zhou Jason Essig of DBMS Consulting 1 Acknowledgements Our sincere thanks to OCUG and the Safety focus
More informationPROACTIVE PHARMACOVIGILANCE
PROACTIVE PHARMACOVIGILANCE RISK BENEFIT A New Model for the 21st Century 21st century technologies will create significant opportunities and challenges for all health care stakeholders. Pharmacovigilance
More informationStatistical Issues in the Analysis of Spontaneous Report Databases
Statistical Issues in the Analysis of Spontaneous Report Databases William DuMouchel, PhD Chief Statistical Scientist Emerging Safety Science Workshop FDA White Oak Conference Center, Silver Spring, MD
More informationPost-marketing Drug Safety Surveillance: Pharmacovigilance in FDA/CDER
Post-marketing Drug Safety Surveillance: Pharmacovigilance in FDA/CDER CSRC/DIA Think Tank June 3, 2016 Oanh Dang, PharmD, BCPS Division of Pharmacovigilance Safety Evaluator Office of Surveillance and
More informationSaudi FDA Drug Approval Process. Dr. Mohammed A. Alquwaizani Consultant- Chief of the scientific office Saudi Food and Drug Authority
Saudi FDA Drug Approval Process Dr. Mohammed A. Alquwaizani Consultant- Chief of the scientific office Saudi Food and Drug Authority Objective Describe the drug regulation practice in Saudi Arabia and
More informationADVERSE drug reactions (ADRs) refer to the drugassociated
826 IEEE TRANSACTIONS ON INFORMATION TECHNOLOGY IN BIOMEDICINE, VOL. 14, NO. 3, MAY 2010 A Distributed, Collaborative Intelligent Agent System Approach for Proactive Postmarketing Drug Safety Surveillance
More informationEuropean Medicines Agency Post-authorisation Evaluation of Medicines for Human Use
European Medicines Agency Post-authorisation Evaluation of Medicines for Human Use London, 26 June 2008 Doc. Ref. EMEA/252216/2007 OVERVIEW OF COMMENTS RECEIVED ON DRAFT GUIDELINE ON THE USE OF STATISTICAL
More informationFDA Requirements 5/16/2011. FDA and new IND regs. Changes on the horizon: CIOMS IX ICH upcoming initiatives
Session Overview (1) Although the role of the Qualified Person responsible for Pharmacovigilance is mandated by the European legislation, the QPPV is held responsible for the establishment and the maintenance
More informationComparing the use of OMOP and Sentinel CDMs for Drug Safety Implications for European Data
Comparing the use of OMOP and Sentinel CDMs for Drug Safety Implications for European Data Andrew Bate Senior Director, Epidemiology Group Lead, Analytics A Common Data Model for Europe? Why? Which? How?
More informationUniversity of Groningen. Improving pharmacovigilance and the role of the pharmacist Grootheest, Adrianus Cornelis van
University of Groningen Improving pharmacovigilance and the role of the pharmacist Grootheest, Adrianus Cornelis van IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF)
More informationGlossary of terms used in Pharmacovigilance
Glossary of terms used in Pharmacovigilance WHO - World Health Organization CIOMS - Council for International Organizations of Medical Sciences ICH - International Conference on Harmonization PSUR - Periodic
More informationDraft Guidance for Industry Development and Use of Risk Minimization Action Plans
Draft Guidance for Industry Development and Use of Risk Minimization Action Plans Docket Number [2004D-0188] Submitted to the U.S. Department of Health and Human Services Food and Drug Administration Center
More informationImportance of Pharmacovigilance for Pharmaceutical Industry
Importance of Pharmacovigilance for Pharmaceutical Industry JARIR AT THOBARI, MD, DPHARM, PHD FACULTY OF MEDICINE GADJAH MADA UNIVERSITY YOGYAKARTA, INDONESIA Role of Pharma Company Globally Investment
More information1201 Maryland Avenue SW, Suite 900, Washington, DC ,
1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org June 19, 2008 Dockets Management Branch (HFA-305) Food and Drug Administration 5600 Fishers Lane, Rm. 1061 Rockville,
More information1201 Maryland Avenue SW, Suite 900, Washington, DC ,
1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org December 28, 2010 Dockets Management Branch (HFA-305) Food and Drug Administration 5600 Fishers Lane, Rm. 1061 Rockville,
More informationOvercoming Statistical Challenges to the Reuse of Data within the Mini-Sentinel Distributed Database
September 5, 2012 September 5, 2012 Meeting Summary Overcoming Statistical Challenges to the Reuse of Data within the Mini-Sentinel Distributed Database With passage of the Food and Drug Administration
More informationPharmacovigilance Methods. The Spectrum of PV
Pharmacovigilance Methods The Spectrum of PV PV Methods: which one? Cohort Event Monitoring Spontaneous Reporting EHR Mining Intensified ADR Reporting Targeted Reporting Record Linkage Geraldine Hill,
More informationImplementing the New Pharmacovigilance Legislation
Implementing the New Pharmacovigilance Legislation Irish Medicines Board, Pharmacovigilance Information Day, Dec 2011 Dr. Almath Spooner Vigilance Assessment Manager, Human Products Monitoring Department
More informationEnsure Generic Drug Safety and Efficacy via a Combined Effort of FDA, Academia, and the Entrepreneurial Industry in a Data-driven Era
Ensure Generic Drug Safety and Efficacy via a Combined Effort of FDA, Academia, and the Entrepreneurial Industry in a Data-driven Era Liang Zhao, Ph.D. Director, Division of Quantitative Methods and Modeling
More informationPolicy Position. Pharmacy-mediated interchangeability for Similar Biotherapeutic Products (SBPs)
Pharmacy-mediated interchangeability for Similar Biotherapeutic Products (SBPs) Geneva, April 2016 Appropriate use of biotherapeutics including SBPs - SBPs, also known as biosimilars, are developed to
More informationUniversity of Groningen. Improving pharmacovigilance and the role of the pharmacist Grootheest, Adrianus Cornelis van
University of Groningen Improving pharmacovigilance and the role of the pharmacist Grootheest, Adrianus Cornelis van IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF)
More informationGuidance for Industry Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment
Guidance for Industry Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions
More informationEphMRA Adverse Event Reporting Guidelines 2016
EphMRA Adverse Event Reporting Guidelines 2016 Based upon the Guideline on good pharmacovigilance practices (GVP) Module VI Management and reporting of adverse reactions to medicinal products European
More informationEmpirical Bayes Model to Combine Signals of Adverse Drug Reactions
Empirical Bayes Model to Combine Signals of Adverse Drug Reactions Rave Harpaz, William DuMouchel,3, Paea LePendu, and Nigam H. Shah Center for Biomedical Informatics Research, Stanford University Oracle
More informationGUIDANCE FOR INDUSTRY Clinical Safety Data Management Definitions and Standards for Expedited Reporting ICH Topic E2A
GUIDANCE FOR INDUSTRY Clinical Safety Data Management Definitions and Published by authority of the Minister of Health 1995 Health Products and Food Branch Guidance Document Our mission is to help the
More informationDose Selection in Drug Development and Regulation: Possible Future Direction. Richard Lalonde and Donald Stanski Pfizer and AstraZeneca
Dose Selection in Drug Development and Regulation: Possible Future Direction Richard Lalonde and Donald Stanski Pfizer and AstraZeneca Overview What is the problem and how did we get here Examples of the
More informationNew EudraVigilance functionalities and the 2010 pharmacovigilance legislation preparing for change
New EudraVigilance functionalities and the 2010 pharmacovigilance legislation preparing for change Training Module PhV-M1 Overview of legal provisions that form the basis for the new EudraVigilance functionalities
More informationPharmacovigilance Playbook (Part 1 of 2)
PHARMACOVIGILANCE AND RISK MANAGEMENT Pharmacovigilance Playbook (Part 1 of 2) Compiled By: Dr. Mufti Suhail Sayeed James Lind Institute www.jliedu.com www.jli.edu.in James Lind Institute www.jliedu.com
More informationCobert's Manual of Drug Safety and Pharmacovigilance
JONES & BARTLETT G Cobert's Manual of Drug Safety and Pharmacovigilance Edition Barton Cobert, MD, FACP, FACG, BLCMD Associates Wcstfield. Jersey Introductions Contributors Noticc. xix. xxi 1 The Thcory
More informationPharmacovigilance. An agency of the European Union
Pharmacovigilance An agency of the European Union Pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse reactions and other medicine-related
More informationThe future of pharmacovigilance: a personal view
Eur J Clin Pharmacol (2008) 64:173 181 DOI 10.1007/s00228-007-0435-9 REVIEW ARTICLE The future of pharmacovigilance: a personal view I. Ralph Edwards Received: 5 October 2007 / Accepted: 27 November 2007
More informationAdverse Event Reporting
Adverse Event Reporting AE Case Receipt When we receive a case, we induct it through a well-oiled process that reduces the number of subsequent queries, classifies events appropriately, and increases the
More informationSocial Media Mining for Drug Safety Signal Detection
Social Media Mining for Drug Safety Signal Detection Christopher C. Yang College of Information Science and Technology Drexel University Philadelphia, PA 19104 Chris.Yang@drexel.edu Ling Jiang College
More informationSonja Brajovic Medical Officer, Office of Surveillance and Epidemiology Center for Drug Evaluation and Research Food and Drug Administration
FDA Perspective on MedDRA Coding Quality in Post marketing Safety Reports European Informal MedDRA User Group Webinar Sonja Brajovic Medical Officer, Office of Surveillance and Epidemiology Center for
More informationADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method] Safety and effectiveness: 10 years of clinical experience
ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method] Safety and effectiveness: 10 years of clinical experience Alfonso Iorio, MD, PhD Health Information Research Unit & Hemophilia Program
More informationData Analytics Pharmacovigilance
Data Analytics in Pharmacovigilance - - Amit Srivastav Founder & Director, Infocorp Software Solution Executive Program in Business Analytics IIM Lucknow - 2014-1 How I Saved 7 Hours Per Day of a PV Org!
More informationSafety reporting requirements in the post marketing phase. Pharmacovigilance Specialty Committee SQA Conference March 2017 Washington
Safety reporting requirements in the post marketing phase Pharmacovigilance Specialty Committee SQA Conference March 2017 Washington DISCLAIMER These materials have been prepared solely for educational
More informationEUDRAVIGILANCE EXPERT WORKING GROUP (EV-EWG) GUIDELINE ON THE USE OF STATISTICAL SIGNAL DETECTION METHODS IN THE EUDRAVIGILANCE DATA ANALYSIS SYSTEM
European Medicines Agency Evaluation of Medicines for Human Use London, 16 November 2006 Doc. Ref. EMEA/106464/2006 EUDRAVIGILANCE EXPERT WORKING GROUP (EV-EWG) GUIDELINE ON THE USE OF STATISTICAL SIGNAL
More informationPharmacovigilance and Patient Safety. Dr M. Roy Jobson Chairperson: Pharmacovigilance Committee of the MCC
Pharmacovigilance and Patient Safety Dr M. Roy Jobson Chairperson: Pharmacovigilance Committee of the MCC Outline Pharmacovigilance The South African Medicines Control Council (MCC) The National Adverse
More informationPHARMA CONGRESS. Pharmacovigilance and Drug Safety: Assessing Future Regulatory and Compliance Developments. October 28, 2008
PHARMA CONGRESS October 28, 2008 Pharmacovigilance and Drug Safety: Assessing Future Regulatory and Compliance Developments Beverly H. Lorell, MD Senior Medical & Policy Advisor King & Spalding LLP Assessing
More informationStrengthening the Pharmacovigilance Programme in Nepal
Strengthening the Pharmacovigilance Programme in Nepal Santosh KC 1, Tragulpiankit P 2, Gorsanan P 3, Edwards IR 4, Alam K 5 1 Senior Pharmacist, Bir Hospital, Kathmandu, Nepal 2 Assistant Professor, Department
More informationWhen and how can Healthcare Database Analyses replace RCTs in marketed medications?
Third Plenary WHEN DO WE REALLY NEED RANDOMIZED CONTROLLED TRIALS? Sebastian Schneeweiss, MD, ScD Brigham & Women s Hospital and Harvard Medical School Boston, MA, USA When and how can Healthcare Database
More informationPharmacovigilance System Master file
IMPLEMENTING MEASURES IN ORDER TO HARMONISE THE PERFORMANCE OF THE PHARMACOVIGILANCE ACTIVITIES PROVIDED FOR IN DIRECTIVE 2001/83/EC AND REGULATION (EC) NO 726/2004 Pharmacovigilance System Master file
More informationQuality Related to Tracked Safety Issues (TSI) An Ophthalmic Case Study
Quality Related to Tracked Safety Issues (TSI) An Ophthalmic Case Study Avin Lalmansingh, Ph.D. CDER/OPQ/OLDP/ Division of Post marketing Activities II 2017 AAM CMC Workshop May 24 th, 2017 DISCLAIMER
More informationVOLUME 9 - PHARMACOVIGILANCE. Medicinal Products for Human and Veterinary Use
VOLUME 9 - PHARMACOVIGILANCE Medicinal Products for Human and Veterinary Use FOREWORD Directive 75/319/EEC as amended by Commission Directive 2000/38/EC of 5 th June 2000 and Directive 81/851/EEC as amended
More informationOfficial Letter from DOH
Issued Date 2008/08/19 Issued by DOH Ref. No 0970329838 RE To announce the Guidance for Good Pharmacovigilance Practice Attachment Guidance for Good Pharmacovigilance Practice Official Letter from DOH
More informationPutting CDISC Standards to Work How Converting to CDISC Standards Early in the Clinical Trial Process Will Make Your CDISC Investment Pay
How Converting to CDISC Standards Early in the Clinical Trial Process Will Make Your CDISC Investment Pay Jon Roth, Vice President, Data Sciences & Biometrics Authorized Trainer for ADaM, CDISC Mark Vieder,
More informationE2B, Safety databases & Eudravigilance
E2B, Safety databases & Eudravigilance Delphine BERTRAM, PharmD Hospices Civils de Lyon France HOT TOPICS IN PV Hod Hasharon 7 May 2014 Dr Irene Fermont- ISOP ISRAEL Dganit Even Sapir -MSD Spontaneous
More informationTranslational Biomedical Informatics and Pharmacometrics Approaches in the Drug Interactions Research
Translational Biomedical Informatics and Pharmacometrics Approaches in the Drug Interactions Research Pengyue Zhang 1, #, Heng-Yi Wu 1, #, Chien-Wei Chiang 1, Lei Wang 1, 2, Samar Binkheder 3, 4, Xueying
More informationharmacovigilance A wake up for
harmacovigilance A wake up for lthcare professionals and the publ repared By: Mr. Sagar D. Kadam Asst.Professor & Admin. Officer HSBPVT s GOI College of Pharmacy, Kashti. Tal. Shrigonda, Dist. Ahmednagar.
More informationQ & A on PSUSA: Guidance document for assessors
31 October 2017 EMA/518909/2016 Human Medicines Evaluation Division Q & A on PSUSA: Guidance document for assessors Since the start of the Periodic Safety Update Report (PSUR) single assessment (PSUSA),
More informationTopic 5: Competency Authors: Jelena Ivanovic; Marco Di Girolamo (Version 4 June 2015)
SCOPE Work Package 8 - LIFECYCLE PHARMACOVIGILANCE Survey Report Topic 5: Competency Authors: Jelena Ivanovic; Marco Di Girolamo (Version 4 June 2015) 1 Introduction 1.1 Purpose of the document The purpose
More informationPharmacovigilance and the Generic Industry
Pharmacovigilance and the Generic Industry Presented by Joan Janulis, RAC Vice President Lachman Consultant Services Inc. 2015 Lachman Consultant Services, Inc. All rights reserved. Legal Notice The information
More informationNew Pharmacovigilance legislation. Post-authorisation safety studies. ENCePP Plenary meeting. 3 May 2012
New Pharmacovigilance legislation Post-authorisation safety studies ENCePP Plenary meeting 3 May 2012 Presented by: Annalisa Rubino, PhV and Risk Management, EMA An agency of the European Union Why? Public
More informationExplanatory Note to GVP Module VII
31 October 2017 EMA/670256/2017 Human Medicines Evaluation Division Explanatory Note to GVP Module VII Since the start of the Periodic Safety Update Report (PSUR) single assessment (PSUSA), the procedure
More informationSAE Reporting Timelines, Causality Assessment And Compensation. Pawandeep Kaur Associate Medical Director CDSA
SAE Reporting Timelines, Causality Assessment And Compensation Pawandeep Kaur Associate Medical Director CDSA Objective Background Important definitions SAE Reporting Timelines Causality Assessment Compensation
More informationPharmacovigilance in the Russian Federation: Construction, Development and Reforms of PV System
Cronicon OPEN ACCESS EC PHARMACOLOGY AND TOXICOLOGY Review Article Pharmacovigilance in the Russian Federation: Construction, Development and Reforms of PV System Gildeeva GN 1 * and Belostotsky AV 2 1Pharmaceutical
More informationDoc. No. DPS/GDL/034 Revision No.: 0 Effective Date: 26 April 2018 Review-Due Date: 26 April 2021
National Drug Authority Head Office Rumee Towers Plot 19, Lumumba Avenue P. O. Box 23096 Kampala, Uganda Tel: 256-0414 - 255665/347391/2 E-mail: ndaug@nda.or.ug Website: http://www.nda.or.ug Doc. No. DPS/GDL/034
More informationWhat s New in GCP? FDA Clarifies, Expands Safety Reporting Guidance
Vol. 9, No. 2, February 2013 Happy Trials to You What s New in GCP? FDA Clarifies, Expands Safety Reporting Guidance Reprinted from the Guide to Good Clinical Practice with permission of Thompson Publishing
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POSITION PAPER ON COMPLIANCE WITH PHARMACOVIGILANCE REGULATORY OBLIGATIONS
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 15 November 2001 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POSITION PAPER ON COMPLIANCE
More information3G SYSTEM IN PHARMACY WITH VIGILANCE
3G SYSTEM IN PHARMACY WITH VIGILANCE OMICS CONFERENCE - 2015 1 CONTENT... Introduction Development of 3G System Importance of Vigilance Pharmacovigilance Program of India (PvPI) High Alert Medication Evaluting
More informationGuideline on good pharmacovigilance practices (GVP)
22 June 2012 EMA/816292/2011 (superseded version) Guideline on good pharmacovigilance practices (GVP) Module VII Periodic safety update report Draft finalised by the Agency in collaboration with Member
More informationAris Global Product Overview. ARISg and ARISj. Extending a Worldwide Pharmacovigilance Program into the Japanese Market
Aris Global Product Overview ARISg and ARISj Extending a Worldwide Pharmacovigilance Program into the Japanese Market Copyright 2010 Aris Global. All rights reserved. POAGAJ1010 No part of this document
More informationThe future of benefit/risk assessment in Europe: The PROTECT programme
The future of benefit/risk assessment in Europe: The PROTECT programme Symposium Relativity in the Evaluation of Medicines What evidence is needed? Xavier Kurz, European Medicines Agency Wallace Collection,
More informationPipeline Drug Evidence Review: Ocrevus (ocrelizumab) vs. Tysabri, Lemtrada, Rebif and Tecfidera June 8, 2016
For more information contact us Pipeline Drug Evidence Review: Ocrevus (ocrelizumab) vs. Tysabri, Lemtrada, Rebif and Tecfidera June 8, 2016 Copyright. 2016 Advera Health Analytics, Inc. All rights reserved.
More informationGuideline on good pharmacovigilance practices (GVP)
9 October 2017 EMA/813938/2011 Rev 3* Guideline on good pharmacovigilance practices (GVP) Module VIII Post-authorisation safety studies (Rev 3) Date for coming into effect of first version 2 July 2012
More informationGuideline on Good Pharmacovigilance Practices Module V- Pharmacovigilance System Master File
Guideline on Good Pharmacovigilance Practices Module V- Pharmacovigilance System Master File Turkish Medicines and Medical Devices Agency 16.02.2015 CHAPTER I... 2 1.1. Introduction... 2 CHAPTER II...
More informationSTATEMENT SANDRA KWEDER, M.D DEPUTY DIRECTOR, OFFICE OF NEW DRUGS CENTER FOR DRUG EVALUATION AND RESEARCH U.S. FOOD AND DRUG ADMINISTRATION BEFORE THE
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville MD 20857 STATEMENT OF SANDRA KWEDER, M.D DEPUTY DIRECTOR, OFFICE OF NEW DRUGS CENTER FOR DRUG EVALUATION
More informationBayesian Measurement of Associations in Adverse Drug Reaction Databases
Bayesian Measurement of Associations in Adverse Drug Reaction Databases William DuMouchel Shannon Laboratory, AT&T Labs Research dumouchel@research.att.com Joint Statistical Meetings, New York City, 13
More informationFDA Experience with the Sentinel Common Data Model: Addressing Data Sufficiency
FDA Experience with the Sentinel Common Data Model: Addressing Data Sufficiency Michael D. Nguyen, MD Office of Surveillance and Epidemiology Center for Drug Evaluation and Research US Food and Drug Administration
More informationHOT TOPICS IN PV. Establishing a good Pharmacovigilance system: Essential elements 2 January 2014 Petach Tikva
HOT TOPICS IN PV International Society of Pharmacovigilance Establishing a good Pharmacovigilance system: Essential elements 2 January 2014 Petach Tikva Dr Irene FERMONT, MD, MSc, EUQPPV ISOP ISRAEL Coordinator
More informationRegulatory Statistical Perspectives on Safety Issues in Drug Development
Regulatory Statistical Perspectives on Safety Issues in Drug Development C. George Rochester, Ph.D. Lead Statistician for Drug Safety Evaluation Food & Drug Administration, Rockville, MD, USA RochesterG@cder.fda.gov
More informationObjectives Discuss the importance of proper data collection. Identify the types of data collected for clinical trials. List potential source documents
Data Management in Clinical Trials Introduction to the Principles and Practice of Clinical Research January 24, 2011 Diane St. Germain, RN, MS, CRNP Nurse Consultant Division of Cancer Prevention National
More informationPharmacovigilance. Dr. Ganesh Uchit, MD Pfizer, India
Pharmacovigilance 1 Dr. Ganesh Uchit, MD Pfizer, India DISCLAIMER The presentation is intended for educational purposes only and does not replace independent professional judgement. Statements of fact
More informationThe Role of the Pharmacist in Pharmacovigilance A Regulatory Perspective
The Role of the Pharmacist in Pharmacovigilance A Regulatory Perspective Almath Spooner, Irish Medicines Board Pharmaceutical Society of Ireland National Pharmacy Summit, November 2008. Presentation Topics
More informationProfessor Francisco José de Abajo, MD, MPH, PhD, Spain
GaBI Scientific Meetings ROUNDTABLE ON BIOSIMILARS Pharmacovigilance, Traceability, Immunogenicity 15 November 2016, Real Academia Nacional de Farmacia, Madrid, Spain Professor Francisco José de Abajo,
More informationApplies to: Signal Management Leads in the Signal Management service (P-PH-SMA) and personnel in the Learning and Development service (A-HR-LAD).
Work instructions Title: Training for signal management leads Applies to: Signal Management Leads in the Signal Management service (P-PH-SMA) and personnel in the Learning and Development service (A-HR-LAD).
More informationDraft agreed by Scientific Advice Working Party 5 September Adopted by CHMP for release for consultation 19 September
23 January 2014 EMA/CHMP/SAWP/757052/2013 Committee for Medicinal Products for Human Use (CHMP) Qualification Opinion of MCP-Mod as an efficient statistical methodology for model-based design and analysis
More information